Clinical Trials Directory

Trials / Completed

CompletedNCT02008734

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in Early Breast Cancer Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
132 (actual)
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a Phase II study trying to identify whether short term treatment with PD0332991 yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at surgery- or induces senescence as determined by SABG expression (IHC) in tumors from patients with early breast cancer non-candidates for neoadjuvant hormonotherapy or chemotherapy, as compared to no treatment.

Conditions

Interventions

TypeNameDescription
DRUGPD0332991

Timeline

Start date
2014-01-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2013-12-11
Last updated
2016-06-09

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02008734. Inclusion in this directory is not an endorsement.